摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3S,4R,5R)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[2-chloro-6-[(2-methylphenyl)methylamino]purin-9-yl]thiolane-2-carboxylic acid | 871913-95-0

中文名称
——
中文别名
——
英文名称
(2S,3S,4R,5R)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[2-chloro-6-[(2-methylphenyl)methylamino]purin-9-yl]thiolane-2-carboxylic acid
英文别名
——
(2S,3S,4R,5R)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[2-chloro-6-[(2-methylphenyl)methylamino]purin-9-yl]thiolane-2-carboxylic acid化学式
CAS
871913-95-0
化学式
C30H46ClN5O4SSi2
mdl
——
分子量
664.416
InChiKey
RZOKENRSWYUJCE-DUOVIKOCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.88
  • 重原子数:
    43
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    137
  • 氢给体数:
    2
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2S,3S,4R,5R)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[2-chloro-6-[(2-methylphenyl)methylamino]purin-9-yl]thiolane-2-carboxylic acid四丁基氟化铵1-羟基苯并三唑1-(3-二甲基氨基丙基)-3-乙基碳二亚胺N,N-二异丙基乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 13.0h, 生成 (2S,3S,4R,5R)-5-[2-chloro-6-[(2-methylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N,N-dimethylthiolane-2-carboxamide
    参考文献:
    名称:
    Structure−Activity Relationships of 2-Chloro-N6-substituted-4‘-thioadenosine-5‘-uronamides as Highly Potent and Selective Agonists at the Human A3 Adenosine Receptor
    摘要:
    We have established structure-activity relationships of novel 4'-thionucleoside analogues as the A(3) adenosine receptor (AR) agonists. Binding affinity, selectivity toward other AR subtypes.. and efficacy in inhibition of adenylate cyclase were studied. From this study, 2-chloro-N-6-methyl-4'-thioadenosine-5'-methyluronamide (36a) emerged as the most potent and selective agonist at the human A(3) AR. We have also revealed that. similar to 4'-oxoadenosine analogues, at least one hydrogen on the 5'-uronamide moiety was necessary for high-affinity binding at the human A(3) AR, presumably to allow this group to donate a H bond within the binding site. Furthermore, bulky substituents on the 5'-uronarnide reduced binding affinity, but in some cases large 5'-uronamide substituents, such as substituted benzyl and 2-phenylethyl groups. maintained moderate affinity with reduced efficacy, leading to A(3) AR partial agonists or antagonists. In several cases for which the corresponding 4'-oxonucleosides have been studied, the 4'-thionucleosides showed higher binding affinity to the A(3) AR.
    DOI:
    10.1021/jm050595e
  • 作为产物:
    参考文献:
    名称:
    Structure−Activity Relationships of 2-Chloro-N6-substituted-4‘-thioadenosine-5‘-uronamides as Highly Potent and Selective Agonists at the Human A3 Adenosine Receptor
    摘要:
    We have established structure-activity relationships of novel 4'-thionucleoside analogues as the A(3) adenosine receptor (AR) agonists. Binding affinity, selectivity toward other AR subtypes.. and efficacy in inhibition of adenylate cyclase were studied. From this study, 2-chloro-N-6-methyl-4'-thioadenosine-5'-methyluronamide (36a) emerged as the most potent and selective agonist at the human A(3) AR. We have also revealed that. similar to 4'-oxoadenosine analogues, at least one hydrogen on the 5'-uronamide moiety was necessary for high-affinity binding at the human A(3) AR, presumably to allow this group to donate a H bond within the binding site. Furthermore, bulky substituents on the 5'-uronarnide reduced binding affinity, but in some cases large 5'-uronamide substituents, such as substituted benzyl and 2-phenylethyl groups. maintained moderate affinity with reduced efficacy, leading to A(3) AR partial agonists or antagonists. In several cases for which the corresponding 4'-oxonucleosides have been studied, the 4'-thionucleosides showed higher binding affinity to the A(3) AR.
    DOI:
    10.1021/jm050595e
点击查看最新优质反应信息

同类化合物

马来酸恩替卡韦 顺式5-氟-1-[2-(羟甲基)-1,3-氧硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮-13C,15N2 顺式5-氟-1-[2-(羟甲基)-1,3-氧硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮 顺-5-氟-1-[2-[[[[(((1,1-二甲基乙基)二甲基甲硅烷基]氧基]甲基]-1,3-氧杂硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮-13C,15N2 顺-5-氟-1-[2-[[[[(((1,1-二甲基乙基)二甲基甲硅烷基]氧基]甲基]-1,3-氧杂硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮 阿巴卡韦羧酸盐 阿巴卡韦相关物质D 阿巴卡韦杂质F 阿巴卡韦杂质 阿巴卡韦中间体A5 阿巴卡韦5’-磷酸酯 阿巴卡韦,拉米夫定混合物 阿巴卡韦 阿巴卡韦 铁(2+)乙二酸酯-丁烷-1-胺(1:1:2) 贝伐西尼 苯甲酸,3-(2-氨基-2-氰基乙酰基)-,乙基酯 芒霉素 艾夫他滨 腺苷基(3'-5')胞苷基(3'-5')胞苷游离酸 腺苷-3',5'-环硫代磷酸酯 腺苷-2',3'-环单硫代磷酸酯,盐内/RP-同质异能素钠 脱氧假尿苷 胸苷酰-(5'-3')-胸苷酰-(5'-3')-胸苷酰-(5'-3')-5'-胸苷酸 胰腺癌RX-3117 硫酸阿巴卡韦 甲基磷羧酸氢[(2S,5R)-5-(4-氨基-2-羰基嘧啶-1(2H)-基)-2,5-二氢呋喃-2-基]甲酯 瓶型酵母D 瓶型酵母A 环戊烯基尿嘧啶 水杨酸拉米呋啶 氟达拉滨EP杂质H 曲沙他滨 拉米夫定相关化合物(Α-TROXACITABINE) 拉米夫定杂质Ⅲ1-[(2R,5S)-2-羟甲基-1,3-氧硫杂环戊-5-基]-嘧啶-2,4(1H,3H)-酮 拉米夫定杂质27 拉米夫定杂质1 拉米夫定单磷酸铵盐 拉米夫定二磷酸酯铵盐 拉米夫定S-氧化物(异构体混合物) 拉米夫定 拉米夫定 拉夫米定EP杂质J 拉夫米定EP杂质H 扎西他宾 恩替卡韦相关物质A 恩替卡韦杂质SSS 恩替卡韦一水合物 恩曲他滨杂质16 恩曲他滨S-氧化物